# A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer

Source: https://onco.cc/ideas/idea-reg-guideline-fast-track-repurposed/  
OnCo record `idea-reg-guideline-fast-track-repurposed` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Guidelines usually wait for a drug to be licensed for a use before recommending it. For old drugs no one will license, guidelines should act directly on trial evidence.

## Summary

Guideline bodies (NCCN, ESMO, NICE) do recommend off-label uses but often slowly and inconsistently for interventions without a sponsor to submit evidence. The proposal is a standing fast-track procedure in major guideline organisations, triggered automatically by publication of a registration-quality randomised trial of an off-patent drug, with a decision within six months, an explicit statement of the recommendation's reimbursement implications, and a mechanism for payers to adopt it in the absence of a label.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Fast-tracked repurposed interventions reach guideline recommendation within six months of publication (versus a historical median of two or more years) and prescribing uptake within two years exceeds 50% of eligible patients.
- Rationale: For off-patent drugs, guidelines rather than labels are the practical gateway to routine use and reimbursement; making the pathway explicit removes an arbitrary disadvantage relative to sponsored drugs.
- Proposed test: Audit the time from publication to guideline inclusion for the last ten positive repurposing trials; implement the fast track in one guideline body and measure the next five.
- Maturity: speculative
- Actor: clinic

## Sources

- Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014): https://doi.org/10.3332/ecancer.2014.442

## Connected records

- collections: [ESMO Clinical Practice Guidelines & MCBS](https://onco.cc/collections/esmo-guidelines/), [NCCN Guidelines](https://onco.cc/collections/nccn/)
- institutions: [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/), [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- bottlenecks: [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/)
- key papers: [The Repurposing Drugs in Oncology (ReDO) Project](https://onco.cc/key-papers/paper-pantziarka-ecancermedicalscience/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-guideline-fast-track-repurposed.json